Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin

AIMS: To assess the efficacy, safety and tolerability of ipragliflozin 50 mg once daily added to sitagliptin 50 mg once daily monotherapy in Japanese patients with type 2 diabetes (T2D). MATERIALS AND METHODS: The results of two clinical trials are reported. In both trials, patients had glycated hae...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaku, Kohei, Kadowaki, Takashi, Seino, Yutaka, Okamoto, Taro, Shirakawa, Masayoshi, Sato, Asako, O'Neill, Edward A., Engel, Samuel S., Kaufman, Keith D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453748/
https://www.ncbi.nlm.nih.gov/pubmed/34033212
http://dx.doi.org/10.1111/dom.14448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453748/
https://www.ncbi.nlm.nih.gov/pubmed/34033212
http://dx.doi.org/10.1111/dom.14448

Ejemplares similares